Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities-Reference-Cited by-同舟云学术

Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities

Published:2021-03 Issue:3 Volume:39 Page:346-360.e7
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

Gay Carl M.^ORCID,Stewart C. Allison^ORCID,Park Elizabeth M.,Diao Lixia,Groves Sarah M.^ORCID,Heeke Simon^ORCID,Nabet Barzin Y.^ORCID,Fujimoto Junya,Solis Luisa M.,Lu Wei,Xi Yuanxin,Cardnell Robert J.,Wang Qi^ORCID,Fabbri Giulia,Cargill Kasey R.^ORCID,Vokes Natalie I.,Ramkumar Kavya,Zhang Bingnan,Della Corte Carminia M.,Robson Paul,Swisher Stephen G.,Roth Jack A.,Glisson Bonnie S.,Shames David S.,Wistuba Ignacio I.,Wang Jing^ORCID,Quaranta Vito,Minna John^ORCID,Heymach John V.,Byers Lauren Averett

Funder

U.S. Department of Defense

National Cancer Institute

Cancer Prevention and Research Institute of Texas

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Oncology

Reference65 articles.

1. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer;Allison Stewart;Oncotarget,2017

2. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial;Antonia;Lancet Oncol.,2016

4. Small cell lung carcinoma subtypes defined by ASCL1, NEUROD1, POU2F3 and YAP1: comprehensive immunohistochemical and histopathologic characterization;Baine;J. Thorac. Oncol. 12, 1823–1835,2020

5. Abstract 5037: targeting MICA with therapeutic antibodies for the treatment of cancer;Bonnafous;J. ImmunoTherapy Cancer,2013

Cited by 538 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comprehensive genomic and spatial immune infiltration analysis of survival outliers in extensive-stage small cell lung cancer receiving first-line chemoimmunotherapy;International Immunopharmacology;2024-11

2. Comprehensive analysis of single-cell transcriptomics and genetic factors reveals the mechanisms and preventive strategies for the progression from pulmonary fibrosis to lung cancer;International Immunopharmacology;2024-10

3. Differential NEUROD1, ASCL1, and POU2F3 Expression Defines Molecular Subsets of Bladder Small Cell/Neuroendocrine Carcinoma With Prognostic Implications;Modern Pathology;2024-10

4. Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer;New England Journal of Medicine;2024-09-13

5. Advances in predictive biomarkers associated with immunotherapy in extensive-stage small cell lung cancer;Cell & Bioscience;2024-09-12